Tego Science Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
1,961
1,534
1,473
754
6,273
Depreciation, Depletion & Amortization
247
284
302
258
231
Other Funds
-
-
40
-
-
Funds from Operations
853
1,977
2,133
2,675
2,568
Changes in Working Capital
106
444
859
159
99
Net Operating Cash Flow
747
1,532
2,992
2,516
2,469
Capital Expenditures
655
3,866
4,450
2,641
9,579
Sale of Fixed Assets & Businesses
2
-
-
-
-
Purchase/Sale of Investments
504
5,244
15,441
13,696
3,306
Net Investing Cash Flow
119
9,710
2,398
15,380
6,230
Cash Dividends Paid - Total
-
-
185
-
-
Issuance/Reduction of Debt, Net
-
-
-
16,100
-
Net Financing Cash Flow
-
7,058
145
16,200
-
Net Change in Cash
629
1,120
449
3,336
3,761
Free Cash Flow
231
2,177
1,099
506
6,895
Other Sources
30
32
208
957
111
Change in Capital Stock
-
7,058
-
100
-
Exchange Rate Effect
-
-
-
-
-
Other Uses
-
632
13,597
-
68

About Tego Science

View Profile
Address
Unit 101 & 102, 1/F
Seoul SL 08505
Korea, Republic Of
Employees -
Website http://www.tegoscience.com
Updated 09/14/2018
Tego Science, Inc. engages in the manufacture and sale of cell therapy products. Its products include Holoderm, Kaloderm, Neoderm, and skin bank and contract research services. The company was founded by Jeon Sae-Wha and Jeon Jae-Wook on March 20, 2001 and is headquartered in Seoul, South Korea.